SUMF2

Summary

SUMF2 (sulfatase modifying factor 2, HGNC:20415) is a protein-coding gene on chromosome 7p11.2, encoding Inactive C-alpha-formylglycine-generating enzyme 2 (Q8NBJ7). Lacks formylglycine generating activity and is unable to convert newly synthesized inactive sulfatases to their active form.

The catalytic sites of sulfatases are only active if they contain a unique amino acid, C-alpha-formylglycine (FGly). The FGly residue is posttranslationally generated from a cysteine by enzymes with FGly-generating activity. The gene described in this record is a member of the sulfatase-modifying factor family and encodes a protein with a DUF323 domain that localizes to the lumen of the endoplasmic reticulum. This protein has low levels of FGly-generating activity but can heterodimerize with another family member - a protein with high levels of FGly-generating activity. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Source: NCBI Gene 25870 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 123 total — 1 pathogenic
• MANE Select transcript: NM_015411

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20415
Approved symbol	SUMF2
Name	sulfatase modifying factor 2
Location	7p11.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp566I1024
Ensembl gene	ENSG00000129103
Ensembl biotype	protein_coding
OMIM	607940
Entrez	25870

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 20 protein_coding, 5 nonsense_mediated_decay, 5 retained_intron

ENST00000275607, ENST00000342190, ENST00000395435, ENST00000395436, ENST00000413756, ENST00000413952, ENST00000423763, ENST00000434526, ENST00000436782, ENST00000437307, ENST00000438133, ENST00000447501, ENST00000451338, ENST00000452216, ENST00000461912, ENST00000483327, ENST00000498777, ENST00000529457, ENST00000531229, ENST00000650735, ENST00000651354, ENST00000651586, ENST00000652303, ENST00000911043, ENST00000911044, ENST00000911045, ENST00000911046, ENST00000966154, ENST00000966155, ENST00000966156

RefSeq mRNA: 9 — MANE Select: NM_015411 NM_001042468, NM_001042469, NM_001042470, NM_001130069, NM_001146333, NM_001366647, NM_001366648, NM_001366649, NM_015411

CCDS: CCDS43588, CCDS43589, CCDS47589, CCDS55111, CCDS5524, CCDS94107

Canonical transcript exons

ENST00000434526 — 9 exons

Exon	Start	End
ENSE00003565405	56078102	56078186
ENSE00003568149	56076834	56076889
ENSE00003598740	56079528	56080670
ENSE00003642638	56074586	56074736
ENSE00003645259	56072997	56073111
ENSE00003672921	56078364	56078508
ENSE00003683911	56074174	56074218
ENSE00003690403	56068482	56068638
ENSE00003901661	56064286	56064378

Expression profiles

Bgee: expression breadth ubiquitous, 246 present calls, max score 98.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 73.0856 / max 302.6621, expressed in 1826 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78774	72.0729	1826
78776	0.9777	640
204451	0.0350	7

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	98.59	gold quality
stromal cell of endometrium	CL:0002255	98.32	gold quality
body of pancreas	UBERON:0001150	98.23	gold quality
gall bladder	UBERON:0002110	97.87	gold quality
endocervix	UBERON:0000458	97.86	gold quality
islet of Langerhans	UBERON:0000006	97.82	gold quality
pancreas	UBERON:0001264	97.82	gold quality
pancreatic ductal cell	CL:0002079	97.54	gold quality
right adrenal gland cortex	UBERON:0035827	97.47	gold quality
right adrenal gland	UBERON:0001233	97.46	gold quality
mucosa of stomach	UBERON:0001199	97.29	gold quality
rectum	UBERON:0001052	97.26	gold quality
right lobe of thyroid gland	UBERON:0001119	97.24	gold quality
right lung	UBERON:0002167	97.21	gold quality
descending thoracic aorta	UBERON:0002345	97.21	gold quality
minor salivary gland	UBERON:0001830	97.19	gold quality
metanephros cortex	UBERON:0010533	97.19	gold quality
left adrenal gland	UBERON:0001234	97.18	gold quality
right coronary artery	UBERON:0001625	97.18	gold quality
skin of leg	UBERON:0001511	97.13	gold quality
right ovary	UBERON:0002118	97.12	gold quality
left ovary	UBERON:0002119	97.08	gold quality
ectocervix	UBERON:0012249	97.08	gold quality
left adrenal gland cortex	UBERON:0035825	97.07	gold quality
body of stomach	UBERON:0001161	97.06	gold quality
smooth muscle tissue	UBERON:0001135	97.04	gold quality
body of uterus	UBERON:0009853	97.03	gold quality
left lobe of thyroid gland	UBERON:0001120	96.99	gold quality
skin of abdomen	UBERON:0001416	96.98	gold quality
thoracic aorta	UBERON:0001515	96.95	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7303	no	1080.37
E-MTAB-4850	no	591.63
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

66 targeting SUMF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6731-5P	99.28	67.42	2375

Literature-anchored findings (GeneRIF, showing 6)

• structural analysis of human pFGE by X-ray crystallography [pFGE] (PMID:15687489)
• pFGE (SUMF2) is the paralog of the Calpha-formylglycine-generating enzyme (PMID:15708861)
• SUMF2 interacts with sulphatase-modifying factor 1 to regulate sulphatase activities. (PMID:15962010)
• pFGE is retained in the ER through its C-terminal tetrapeptide PGEL, a noncanonical variant of the classic KDEL ER-retention signal. (PMID:18266766)
• SUMF2 interacted with IL-13 and inhibited IL-13 secretion in bronchial smooth muscle cells and lymphocytes, which was independent of IL-13 glycosylation (PMID:19739097)
• Differential DNA methylation analysis of SUMF2, ADAMTS5, and PXDN provides novel insights into colorectal cancer prognosis prediction in Taiwan. (PMID:35317099)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	sumf2	ENSDARG00000069497
mus_musculus	Sumf2	ENSMUSG00000025538
rattus_norvegicus	Sumf2	ENSRNOG00000000922

Paralogs (1): SUMF1 (ENSG00000144455)

Protein

Protein identifiers

Inactive C-alpha-formylglycine-generating enzyme 2 — Q8NBJ7 (reviewed: Q8NBJ7)

Alternative names: Paralog of formylglycine-generating enzyme, Sulfatase-modifying factor 2

All UniProt accessions (15): Q8NBJ7, A0A494C1B1, A8MXB9, C9J660, C9JL30, E9PBT8, E9PG02, F8WA42, F8WCW9, F8WES7, F8WEV7, F8WEX5, H7C3B2, J3KQJ1, J3QT17

UniProt curated annotations — full annotation on UniProt →

Function. Lacks formylglycine generating activity and is unable to convert newly synthesized inactive sulfatases to their active form. Inhibits the activation of sulfatases by SUMF1.

Subunit / interactions. Homodimer and heterodimer with SUMF1.

Subcellular location. Endoplasmic reticulum lumen.

Tissue specificity. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Highest levels in kidney, liver and placenta.

Domain organisation. The non-canonical ER retention motif mediates retention of the protein in the endoplasmic reticulum.

Similarity. Belongs to the sulfatase-modifying factor family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q8NBJ7-1	1	yes
Q8NBJ7-2	2
Q8NBJ7-3	3
Q8NBJ7-5	5
Q8NBJ7-4	4

RefSeq proteins (9): NP_001035933, NP_001035934, NP_001035935, NP_001123541, NP_001139805, NP_001353576, NP_001353577, NP_001353578, NP_056226* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005532	SUMF_dom	Domain
IPR016187	CTDL_fold	Homologous_superfamily
IPR042095	SUMF_sf	Homologous_superfamily
IPR051043	Sulfatase_Mod_Factor_Kinase	Family

Pfam: PF03781

UniProt features (46 total): strand 12, binding site 8, helix 7, mutagenesis site 5, splice variant 4, sequence variant 2, signal peptide 1, chain 1, glycosylation site 1, disulfide bond 1, region of interest 1, short sequence motif 1, turn 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1Y4J	X-RAY DIFFRACTION	1.86

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NBJ7-F1	91.37	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 232; 234; 236; 194; 195; 208; 210; 229

Disulfide bonds (1): 156–290

Glycosylation sites (1): 191

Mutagenesis-validated functional residues (5):

Position	Phenotype
156	abolishes interaction with and inhibition of sumf1. can still form homodimers.
290	abolishes interaction with and inhibition of sumf1. can still form homodimers.
298–301	abolishes endoplasmic reticulum retention.
298–299	does not affect endoplasmic reticulum retention.
298	does not affect endoplasmic reticulum retention.

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-1663150	The activation of arylsulfatases
R-HSA-9840310	Glycosphingolipid catabolism
R-HSA-1430728	Metabolism
R-HSA-163841	Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
R-HSA-1660662	Glycosphingolipid metabolism
R-HSA-392499	Metabolism of proteins
R-HSA-428157	Sphingolipid metabolism
R-HSA-556833	Metabolism of lipids
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 79 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, REACTOME_SPHINGOLIPID_METABOLISM, GCM_NF2, ACEVEDO_LIVER_CANCER_UP, GOCC_ENDOPLASMIC_RETICULUM_LUMEN, YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, MIKKELSEN_ES_ICP_WITH_H3K4ME3, MIKKELSEN_NPC_ICP_WITH_H3K4ME3, CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN, GCM_DENR, REACTOME_GAMMA_CARBOXYLATION_HYPUSINYLATION_HYDROXYLATION_AND_ARYLSULFATASE_ACTIVATION, REACTOME_METABOLISM_OF_LIPIDS, ATF6_TARGET_GENES, DLX2_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (3): identical protein binding (GO:0042802), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (2): endoplasmic reticulum (GO:0005783), endoplasmic reticulum lumen (GO:0005788)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1
Glycosphingolipid metabolism	1
Post-translational protein modification	1
Sphingolipid metabolism	1
Metabolism of lipids	1
Metabolism	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	1
cation binding	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
endoplasmic reticulum	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1141 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SUMF2	ZNF713	Q8N859	651
SUMF2	PHKG1	Q16816	642
SUMF2	CCT6A	P40227	600
SUMF2	NIPSNAP2	O75323	562
SUMF2	CHCHD2	Q9Y6H1	519
SUMF2	ERP44	Q9BS26	498
SUMF2	LMAN1	P49257	495
SUMF2	SUMF1	Q8NBK3	489
SUMF2	PSPH	P78330	467
SUMF2	MXRA7	P84157	463
SUMF2	FOXRED2	Q8IWF2	452
SUMF2	ATRAID	Q6UW56	450
SUMF2	SEPTIN14	Q6ZU15	445
SUMF2	TMEM161B	Q8NDZ6	443
SUMF2	NUPR2	A6NF83	442

IntAct

69 interactions, top by confidence:

A	B	Type	Score
SUMF1	SGSH	psi-mi:“MI:0914”(association)	0.710
SUMF2		psi-mi:“MI:0915”(physical association)	0.660
SUMF1	SUMF2	psi-mi:“MI:0915”(physical association)	0.640
SUMF2	SUMF1	psi-mi:“MI:0915”(physical association)	0.640
SUMF1	SUMF2	psi-mi:“MI:0403”(colocalization)	0.640
SUMF2	APBB2	psi-mi:“MI:0915”(physical association)	0.560
SUMF2	CTSD	psi-mi:“MI:0915”(physical association)	0.560
SUMF2		psi-mi:“MI:0915”(physical association)	0.560
GRN	SUMF2	psi-mi:“MI:0915”(physical association)	0.560
SUMF2	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
SUMF2	PMP22	psi-mi:“MI:0915”(physical association)	0.560
SUMF2	TTR	psi-mi:“MI:0915”(physical association)	0.560
SUMF2	WFS1	psi-mi:“MI:0915”(physical association)	0.560
SUMF2	KIF1B	psi-mi:“MI:0915”(physical association)	0.560
HTT	SUMF2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (78): SUMF2 (Two-hybrid), ANKRD40 (Affinity Capture-MS), APOD (Affinity Capture-MS), CLU (Affinity Capture-MS), WDR34 (Affinity Capture-MS), APOD (Affinity Capture-MS), ANKRD40 (Affinity Capture-MS), SUMF2 (Affinity Capture-MS), SUMF2 (Co-fractionation), SUMF2 (Co-fractionation), SUMF2 (Co-fractionation), GRHPR (Co-fractionation), SUMF2 (Co-fractionation), SUMF2 (Co-fractionation), ABHD11 (Co-fractionation)

ESM2 similar proteins: A0R5N0, A0R6E0, D1A7C3, G7CFI3, I6Y8I5, O69671, P0A4Y5, P0A5F6, P16954, P28604, P45798, P71741, P9WIQ8, P9WIQ9, P9WQ18, P9WQ19, P9WQ24, P9WQ25, Q0AA26, Q0BU54, Q11EX1, Q1D654, Q1QJC0, Q210H1, Q216J6, Q28MN2, Q2IYX0, Q2J6Q9, Q2RR72, Q2W2Q6, Q2YB47, Q3AYE2, Q3SMH1, Q46TF2, Q47SE7, Q58CP2, Q59832, Q5N4W5, Q5NXV7, Q5RCR5

Diamond homologs: A0A0H3MBJ2, D1A7C3, O69671, P0DPS7, Q0P5L5, Q58CP2, Q5RCR5, Q7AJA5, Q7D513, Q822R1, Q8NBJ7, Q8R0F3, Q9F3C7, Q9PKP3, A0R5N0, G7CFI3, Q8BPG6, Q8NBK3, I6Y8I5, V9TSX0, Q7RX33, O94632, O34722

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

123 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	86
Likely benign	11
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2678	NM_015411.4(SUMF2):c.536-2del	Pathogenic

SpliceAI

1515 predictions. Top by Δscore:

Variant	Effect	Δscore
7:56064374:GCTAG:G	donor_gain	1.0000
7:56064375:C:G	donor_gain	1.0000
7:56064377:AGG:A	donor_loss	1.0000
7:56064378:GGT:G	donor_loss	1.0000
7:56068478:GCA:G	acceptor_loss	1.0000
7:56068479:CAG:C	acceptor_loss	1.0000
7:56068480:AG:A	acceptor_gain	1.0000
7:56068481:G:A	acceptor_loss	1.0000
7:56068481:GG:G	acceptor_gain	1.0000
7:56068481:GGA:G	acceptor_gain	1.0000
7:56068481:GGAA:G	acceptor_gain	1.0000
7:56074748:A:G	donor_gain	1.0000
7:56076787:A:AG	acceptor_gain	1.0000
7:56078097:A:AG	acceptor_gain	1.0000
7:56078097:ATCAG:A	acceptor_gain	1.0000
7:56078100:A:AG	acceptor_gain	1.0000
7:56078100:AG:A	acceptor_gain	1.0000
7:56078100:AGG:A	acceptor_gain	1.0000
7:56078101:G:GA	acceptor_gain	1.0000
7:56078101:GG:G	acceptor_gain	1.0000
7:56078101:GGG:G	acceptor_gain	1.0000
7:56078101:GGGA:G	acceptor_gain	1.0000
7:56078101:GGGAA:G	acceptor_gain	1.0000
7:56078184:ACGGT:A	donor_loss	1.0000
7:56078185:CGGT:C	donor_loss	1.0000
7:56078186:GGT:G	donor_loss	1.0000
7:56078187:G:GG	donor_gain	1.0000
7:56078187:GTA:G	donor_loss	1.0000
7:56078188:T:C	donor_loss	1.0000
7:56064379:G:GG	donor_gain	0.9900

AlphaMissense

1954 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:56078396:T:A	W237R	0.996
7:56078396:T:C	W237R	0.996
7:56074210:T:A	W126R	0.995
7:56074210:T:C	W126R	0.995
7:56073049:A:C	S93R	0.994
7:56073051:C:A	S93R	0.994
7:56073051:C:G	S93R	0.994
7:56074212:G:C	W126C	0.994
7:56074212:G:T	W126C	0.994
7:56074643:A:C	S148R	0.993
7:56074645:C:A	S148R	0.993
7:56074645:C:G	S148R	0.993
7:56074669:T:G	C156W	0.993
7:56078398:G:C	W237C	0.993
7:56078398:G:T	W237C	0.993
7:56079569:T:C	F288S	0.993
7:56074708:G:C	W169C	0.992
7:56074708:G:T	W169C	0.992
7:56074706:T:A	W169R	0.991
7:56074706:T:C	W169R	0.991
7:56078386:C:A	N233K	0.991
7:56078386:C:G	N233K	0.991
7:56078392:G:C	W235C	0.991
7:56078392:G:T	W235C	0.991
7:56074716:C:A	A172D	0.990
7:56076850:G:C	W184C	0.990
7:56076850:G:T	W184C	0.990
7:56078454:C:T	S256F	0.990
7:56068635:T:C	F74S	0.989
7:56074668:G:A	C156Y	0.989

dbSNP variants (sampled 300 via entrez): RS1000370165 (7:56073776 C>T), RS1000385302 (7:56081391 G>A), RS1000650644 (7:56079652 A>G), RS1000681720 (7:56079853 A>G), RS1000705531 (7:56075433 A>G), RS1000759113 (7:56075652 T>C,G), RS1000776892 (7:56080079 C>T), RS1000831888 (7:56085417 G>A), RS1000925152 (7:56063059 G>A), RS1000956411 (7:56088151 C>T), RS1000975607 (7:56063258 T>A), RS1001668431 (7:56080770 T>A), RS1001689290 (7:56088315 C>A), RS1001764386 (7:56086164 T>A), RS1001987926 (7:56073458 A>G)

Disease associations

OMIM: gene MIM:607940 | disease phenotypes: MIM:272200

GenCC curated gene-disease

Mondo (1): mucosulfatidosis (MONDO:0010088)

Orphanet (1): Multiple sulfatase deficiency (Orphanet:585)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST007382_32	Plasma free amino acid levels (adjusted for twenty other PFAAs)	1.000000e-25
GCST007385_29	Plasma free amino acid levels	2.000000e-21
GCST012251_16	Macular telangiectasia type 2	3.000000e-07
GCST012252_7	Macular telangiectasia type 2	6.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005134	amino acid measurement
EFO:0009774	serine measurement
EFO:1002009	macular telangiectasia type 2

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D052517	Multiple Sulfatase Deficiency Disease	C10.228.140.163.100.435.825.850.750; C16.320.565.189.435.825.850.750; C16.320.565.398.641.803.925.750; C16.320.565.595.554.825.850.750; C18.452.132.100.435.825.850.750; C18.452.584.563.641.803.925.750; C18.452.648.189.435.825.850.750; C18.452.648.398.641.803.925.750; C18.452.648.595.554.825.850.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	2
sodium arsenite	decreases expression, increases abundance	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Cisplatin	affects expression, affects cotreatment, increases expression	2
Ozone	affects expression, increases abundance, affects cotreatment, increases oxidation	2
Valproic Acid	increases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
tetrabromobisphenol A	decreases expression	1
methacrylaldehyde	increases oxidation, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
calfactant	affects cotreatment, increases expression	1
K 7174	increases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Decitabine	affects expression	1
Acrolein	affects cotreatment, increases oxidation	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Doxorubicin	decreases expression	1
Gallic Acid	decreases expression	1
Ivermectin	decreases expression	1
Plant Extracts	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

6 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01841983	Not specified	COMPLETED	Project A: Integrated Approaches to Improving the Health and Safety of Health Care Workers
NCT02699190	Not specified	COMPLETED	LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT03047369	Not specified	RECRUITING	The Myelin Disorders Biorepository Project
NCT03333200	Not specified	RECRUITING	Longitudinal Study of Neurodegenerative Disorders
NCT03831737	Not specified	COMPLETED	Team-based Ergonomics Educational Model for Workplace WELLNESS Improvement: A Pilot Study
NCT06036693	Not specified	RECRUITING	MPS (RaDiCo Cohort) (RaDiCo-MPS)